SCHEMBL25337035

SCHEMBL25337035

CC(C)(C)OC(=O)N1CCN(c2nc3cccc(N4CCC(=O)NC4=O)c3s2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 7/20 0.46
CRBN Q96SW2 7/20 0.46
GPR119 Q8TDV5 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
BACE1 P56817 2/20 0.41
GBA1 P04062 2/20 0.40
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OGFRL1 Q5TC84 1/20 0.39
PARP1 P09874 2/20 0.39
NAAA Q02083 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
MAP4K4 O95819 1/20 0.39
SMARCA2 P51531 1/20 0.38
SMARCA4 P51532 1/20 0.38
PBRM1 Q86U86 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29506979 1.00 DDB1 (0.46) DDB1CRBNGPR119NPC1RAB9A
SCHEMBL26683776 0.86 CRBN (0.40) DDB1CRBNNPC1RAB9ANAAA
SCHEMBL20767907 0.80 NPC1 (0.50) GPR119NPC1RAB9AGBA1PARP1
SCHEMBL25337466 0.80 CRBN (0.43) DDB1CRBNGPR119NPC1RAB9A
SCHEMBL26683685 0.79 CRBN (0.43) DDB1CRBNNPC1RAB9A
SCHEMBL30688286 0.79 CRBN (0.43) DDB1CRBNNPC1RAB9A
SCHEMBL20767921 0.78 NPC1 (0.48) GPR119NPC1RAB9ABACE1GBA1
SCHEMBL20767904 0.78 NAAA (0.59) GPR119NPC1RAB9AGBA1NAAA
SCHEMBL20767864 0.77 NPC1 (0.47) GPR119NPC1RAB9AGBA1NAAA
SCHEMBL24607451 0.77 DDB1 (0.48) DDB1CRBNGPR119BACE1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2023-11-23 US disclosed
EP-4221756-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2023-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374007-A1 COMPOUNDS AND THEIR USE IN TREATING CANCER RARA, RARG, RARB DDB1 4162/4885CRBN 2312/4885GPR119 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.